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of age, associated with onset of neurodegeneration. Treat-
ment with the PERK inhibitor, GSK2606414, from this 
time point in mutant tau-expressing mice restores protein 
synthesis rates, protecting against further neuronal loss, 
reducing brain atrophy and abrogating the appearance of 
clinical signs. Further, we show that PERK-eIF2α activa-
tion also contributes to the pathological phosphorylation 
of tau in rTg4510 mice, and that levels of phospho-tau are 
lowered by PERK inhibitor treatment, providing a second 
mechanism of protection. The data support UPR-medi-
ated translational failure as a generic pathogenic mecha-
nism in protein-misfolding disorders, including tauopa-
thies, that can be successfully targeted for prevention of 
neurodegeneration.
Keywords Unfolded Protein Response · Tau · 
Neurodegeneration · Dementia · PERK
Introduction
Endoplasmic reticulum (ER) stress and its associated 
Unfolded Protein Response (UPR) are emerging as major 
common themes in neurodegenerative disorders [13, 33]. 
The modulation of proteostasis is increasingly a potential 
therapeutic target in a wide range of human diseases associ-
ated with protein misfolding [12]. The UPR involves three 
major signalling cascades that enable the cell to deal with 
the build up of misfolded (or unfolded) proteins, which are 
detected by sensors within the ER [30]. One branch of the 
UPR, mediated by protein kinase RNA (PKR)-like/Pan-
creatic ER kinase (PERK), leads to the transient shutdown 
of protein synthesis. Activated (phosphorylated) PERK 
(PERK-P) phosphorylates the alpha subunit of eukaryotic 
initiation factor 2 (eIF2α); this inhibits the initiation of 
Abstract The PERK-eIF2α branch of the Unfolded Pro-
tein Response (UPR) mediates the transient shutdown of 
translation in response to rising levels of misfolded pro-
teins in the endoplasmic reticulum. PERK and eIF2α acti-
vation are increasingly recognised in postmortem analyses 
of patients with neurodegenerative disorders, including 
Alzheimer’s disease, the tauopathies and prion disorders. 
These are all characterised by the accumulation of mis-
folded disease-specific proteins in the brain in association 
with specific patterns of neuronal loss, but the role of UPR 
activation in their pathogenesis is unclear. In prion-diseased 
mice, overactivation of PERK-P/eIF2α-P signalling results 
in the sustained reduction in global protein synthesis, lead-
ing to synaptic failure, neuronal loss and clinical disease. 
Critically, restoring vital neuronal protein synthesis rates 
by inhibiting the PERK-eIF2α pathway, both genetically 
and pharmacologically, prevents prion neurodegeneration 
downstream of misfolded prion protein accumulation. Here 
we show that PERK-eIF2α-mediated translational failure is 
a key process leading to neuronal loss in a mouse model of 
frontotemporal dementia, where the misfolded protein is a 
form of mutant tau. rTg4510 mice, which overexpress the 
P301L tau mutation, show dysregulated PERK signalling 
and sustained repression of protein synthesis by 6 months 
 * Giovanna R. Mallucci 
 gm522@cam.ac.uk
1 MRC Toxicology Unit, Hodgkin Building, University 
of Leicester, Lancaster Road, Leicester LE1 9HN, UK
2 Department of Microbiology, Immunology and Pathology, 
Prion Research Center, Colorado State University, Fort 
Collins, CO 80523-1619, USA
3 Department of Clinical Neurosciences, University 
of Cambridge, Cambridge CB2 0AH, UK
634 Acta Neuropathol (2015) 130:633–642
1 3
translation and induces expression of the transcription fac-
tor ATF4, and associated downstream signalling events, 
including induction of GADD34, the stress-induced eIF2α-
P-specific phosphatase. (eIF2α can also be phosphorylated 
by other kinases as part of the integrated stress response 
(ISR), in response to cellular stresses such as viral infection 
and amino acid starvation). Increased PERK-P and eIF2α-P 
have been reported in postmortem analyses of brains from 
patients with Alzheimer’s disease (AD), Parkinson’s dis-
ease (PD) and the tauopathies Progressive Supranuclear 
Palsy (PSP) and Frontotemporal Dementia (FTD), as well 
as in prion disease [3, 15, 16, 37, 38]. In AD patients, UPR 
activation is thought to occur early in disease pathology in 
association with the accumulation of abnormal phosphoryl-
ated tau in neurons, but before neurofibrillary tangle forma-
tion [16, 26]. PERK-P staining has also been shown to be 
associated with phospho-tau-positive neurons in CA1 and 
dentate gyrus and subiculum regions of the hippocampus in 
FTD-tau cases [26].
However, it is unclear what the pathological signifi-
cance of these findings is for the human diseases; spe-
cifically, whether they reflect activation of a protective 
mechanism or the signature of a pathogenic process (see 
Scheper and Hoozemans, for review [33]). This is of key 
significance for both mechanistic understanding and for 
development of potential treatments. Important insights 
come from animal models. PERK branch UPR overactiva-
tion occurs in several mouse models of neurodegenerative 
disease, including AD [1, 9, 13], prion [24], tauopathy [1, 
18] and ALS [3, 32]. In prion-diseased mice, accumulation 
of misfolded prion protein (PrP) causes persistently high 
levels of PERK-P and eIF2α-P, and hence sustained trans-
lational failure. This results in a catastrophic decline in 
levels of key synaptic proteins, leading to synaptic failure 
and ultimately to neuronal loss [24]. This is true for both 
PrP overexpressing mice and for wild-type mice, support-
ing that PERK-eIF2α overactivation is not an artefact of 
high levels of protein expression, but occurs at endogenous 
levels (consistent with observations in humans). Critically, 
both genetic manipulations that reduce eIF2α-P levels [24] 
and pharmacological inhibition of PERK using the inhibi-
tor GSK2606414 [4], or with the small molecule inhibitor, 
ISRIB, which acts downstream of eIF2α-P, restored vital 
protein synthesis rates and prevented neurodegeneration 
and clinical disease in prion-infected mice [11, 23, 24]. In 
contrast, pharmacological treatment preventing the reduc-
tion of eIF2α-P levels accelerated disease and exacerbated 
toxicity in prion-diseased mice [24]. Given the range of 
neurodegenerative diseases in which PERK branch UPR 
dysregulation is seen, it is crucial to understand its role in 
mediating neuronal loss in protein-misfolding disorders 
more broadly, particularly in AD and other dementias. 
This will also help determine its potential as a therapeu-
tic target in these disorders. Wider relevance of the path-
way in AD is supported by the fact that both PERK hap-
loinsufficiency [9] and genetic suppression of other eIF2α 
kinases [21] rescue memory deficits and neurodegenera-
tion in mouse models of AD. Indeed, neuronal eIF2α-P 
levels—and hence rates of protein synthesis—in wild-type 
mice are key to learning and memory [6], and pharmaco-
logical inhibition of eIF2α-P signalling boosts cognition 
[35]. Further, with relevance for AD and other tauopa-
thies, PERK branch UPR activation is also known to con-
tribute to the phosphorylation of tau—which is central 
to pathology in these diseases—both in vitro and in vivo 
[14, 20, 39]. In vitro, this has been shown to be due to 
PERK-mediated induction of glycogen synthase kinase-3 
(GSK3β), a serine/threonine kinase that phosphorylates 
tau at disease-relevant epitopes [25], an effect that can be 
reversed by PERK inhibition [39]. Thus, UPR activation 
may have a dual pathological role in tauopathies, impact-
ing on two processes fundamental to neurodegeneration in 
these disorders.
We have now examined the role of PERK pathway acti-
vation in the rTg4510 mouse model of FTD caused by the 
human tau P301L mutation [29, 31]. Mice positive for the 
mutant tau transgene (tau+P301L) show high levels of P301L 
tau expression throughout their lives, with age-related tau 
pathology, progressive memory deficits and, importantly, 
extensive forebrain neurodegeneration from 5.5 months of 
age [29, 31]. Tau+P301L rTg4510 mice show abnormal con-
formations of tau from 2.5 months, with pre-tangle hyper-
phosphorylated tau detected by 4 months of age, with the 
appearance of mature neurofibrillary tangles and neuro-
degeneration in the hippocampus from 5.5 months. Neu-
ronal loss becomes widespread throughout the forebrain 
after 7 months of age, leading to marked forebrain atrophy 
associated with clinical signs of poor grooming and motor 
impairment. Transgene-negative (tau−P301L) rTg4510 mice 
have normal brain morphology, behaviour and appearance 
and do not show phosphorylated tau [29, 31]. Increased 
levels of PERK-P in the brain of these mice have been 
reported during later disease stages (from 9 months), 
although the role of PERK-P signalling in mediating neu-
rodegeneration in these animals has not previously been 
examined [1].
We first confirmed activation of PERK-eIF2α signalling 
in rTg4510 mice due to mutant tau expression. We then 
examined the effects of therapeutic inhibition of PERK sig-
nalling on both rates of neuronal protein synthesis and on 
tau phosphorylation and their role in neurodegeneration in 
these animals.




All animal work conformed to the UK Home Office regu-
lations and institutional guidelines. rTg4510 tau+P301L and 
tau−P301L mice were obtained from Eli Lilly and Company. 
Treatment with doxycycline was performed from 4 months 
of age, by oral dosing as described [31]. rTg4510 mice 
were given two oral (bolus) doses of 10 mg/kg, then fol-
lowed by Harlan Teklad T-7012, 200 diet with doxycy-
cline 200 mg/kg in chow (n = 6 female mice). Treatment 
with GSK2606414 was by oral gavage twice daily with 
50 mg/kg GSK2606414 suspended in vehicle (0.5 % 
HPMC + 0.1 % Tween-80 in H2O at pH 4.0) (n = 10 
male), or with vehicle alone (n = 8 male) as described [23] 
from ~6 months of age.
Western blotting
Protein extraction from hippocampi and immunoblots of 
UPR and synaptic proteins were performed as described 
[23, 24]. Proteins were detected with the following anti-
bodies: eIF2α-P (S51) (1:1000; 9721, Cell Signaling) 
and eIF2α (L57A5) (1:1000; 2103, Cell Signaling), ATF4 
(CREB-2, 1:1000; sc-200, Santa Cruz), GADD34 (1:1000, 
10449-1-AP, Proteintech), PERK-P (1:200, 32577, Santa 
Cruz), PERK (1:1000, 3192, Cell Signaling), SNAP25 
(1:10,000, ab5666, Abcam), PSD-95 (1:1000, EP2652Y, 
Millipore) total tau (Tau 5, 1:5000, AHB0041, Invitro-
gen), GSK3β (1:2000, 9832, Cell Signaling), pSer9-GSK3β 
(1:1000, 9322, Cell Signaling) and pTyr279/216-GSK3α/β 
(1:1000, 05-413, Millipore). Horseradish peroxidase 
(HRP)-conjugated secondary antibodies (1:10,000; DAKO) 
were applied, and protein was visualised using enhanced 
chemiluminescence (GE Healthcare) and quantitated using 
ImageJ. Antibodies against GAPDH (1:5000; sc-32233, 
Santa Cruz) and Beta-III-tubulin (1:5000, MAB1637, Mil-
lipore) were used to determine loading.
Protein synthesis rates
Global translational levels (protein synthesis rates) were 
calculated by measuring 35S-methionine incorporation into 
proteins in acute hippocampal slices, as described [23, 24]. 
Briefly, slices were incubated with 5.7 mBq of 35S-methio-
nine label in oxygenated artificial cerebrospinal fluid at 
37 °C for 1 h. Incorporation of radiolabel was measured 
by scintillation counting (WinSpectral, Wallac Inc.). All 
biochemical analyses were performed in hippocampi from 
three to four mice.
Histology
Paraffin-embedded brains were sectioned at 5 μm and 
stained with haematoxylin and eosin or NeuN antibody 
(1:200; MAB377, Millipore) for neuronal counts as 
described [23, 24]. CA1 pyramidal neuron counts were 
determined using three serial sections from three to four 
separate mice [24]. All neuronal counting was performed 
with the investigator being blind to the sample group being 
analysed. Immunohistochemistry for pSer202/Thr205 tau was 
performed using AT8 (1:100; MN1020, Thermo Scientific). 
Non-specific binding was blocked prior to primary anti-
bodies using Histostain-Plus Bulk kit (Invitrogen). A bioti-
nylated secondary antibody (Invitrogen) was used and stain 
visualised by diaminobenzidine reagent. All images were 
taken on using Axiovision 4.8 software (Zeiss) and counted 
using Volocity imaging system (Version 6.3) [24]. Immu-
nofluorescence for pSer202/Thr205 tau was performed using 
AT8 (1:100; MN1020, Thermo Scientific) and PERK-P 
(1:50, 32577, Santa Cruz). Sections were blocked and per-
meabilized in blocking buffer (2 % donkey serum, 0.2 % 
Triton X-100 in TBS) for 1 h and then incubated overnight 
at 4 °C with primary antibody in TBS+2 % serum. Alexa 
Fluor 488 nm and 594 nm (1:500, Invitrogen) were then 
applied for 1 h. Slides were then mounted with VECTASH-
IELD Mounting media with DAPI (Vector laboratories). 
All images were taken using Zeiss LSM510 confocal 
microscope and counted using Volocity imaging system.
Phospho‑tau biochemical analysis
To detect levels of phosphorylated tau in total lysates 
AlphaScreen assays (Amplified Luminescent Proximity 
Homogeneous Assay Screen) were performed as described 
in [2] and as per manufacturer’s instructions. Phospho-tau-
specific AT8 (pSer202/Thr205 tau) and PHF1 (pSer369/404 tau) 
antibodies were used. Briefly, optimised antibody/accep-
tor bead mix was incubated overnight at 4 °C with sam-
ple lysate or standard diluted in AlphaScreen assay buffer. 
Next, streptavidin-coated donor beads were added and 
incubated in the dark at room temperature for 4 h. Plates 
were read at excitation 680 nm and emission 520–620 nm 
using an Envision plate reader.
XBP1‑splicing assay
Total RNA was extracted from hippocampi with the 
mirVana isolation kit (Ambion). RNA samples were 
reversed-transcribed with oligo(dT) primers using 
ImProm-II Reverse Transcriptase (Promega). XBP1 
mRNA was amplified with primers flanking the 26b intron 
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(5′-GGAGTGGAGTAAGGCTGGTG and 5′-CCAGAAT-
GCCCAAAAGGATA) using Phusin High-Fidelity taq pol-
ymerase (New England Biolabs) [23]. PCR products were 
resolved on 3 % agarose gels. MEF cells were treated with 
5 μg/ml tunicamycin for 6 h and used as a positive control 
for XBP1 splicing.
Statistics
All statistical analyses were performed using Prism V6 
software using Student’s t test for data sets with normal 
distribution and a single intervention. ANOVA testing was 
performed using one-way analysis with Tukey’s post hoc 
test for multiple comparisons.
Results and discussion
High levels of total mutant tau expression lead 
to activation of the PERK branch of the UPR 
and sustained translational repression in rTg4510 FTD 
mice
We assessed PERK branch UPR activation in the brains 
of rTg4510 mice by measuring levels of eIF2α-P, ATF4, 
GADD34 and global protein synthesis rates over the course 
of disease. P301L transgene-expressing mice (tau+P301L) 
express high levels of mutant tau from birth (repressible by 
doxycycline administration [31]). Characteristically, they 
show memory impairment and hippocampal neuronal loss 
by 6 months, with widespread forebrain atrophy and overt 
clinical signs by 8 months [29, 31] (Fig. 1a). We tested 
mice from 4 months of age. All tau+P301L mice expressed 
high levels of total tau compared to low levels in non-trans-
genic controls, which express only wild-type (murine) tau 
(Fig. 1b).
Levels of eIF2α-P and ATF4 were low in all animals 
until 6 months of age, by which time there was marked 
elevation of eIF2α-P and ATF4 levels in tau+P301L mice 
compared to non-transgenic littermates (Fig. 1b), con-
sistent with activation of PERK signalling. Interestingly, 
GADD34 levels did not increase over time (Fig. 1b), 
which is unexpected given induction of ATF4, but consist-
ent with the effects of PERK branch overactivation seen in 
prion-infected mice [24]. The failure to induce GADD34 
would explain the persistent high levels of eIF2α-P seen 
in tau+P301L older mice (Fig. 1b), again similar to the sus-
tained elevation of eIF2α-P levels seen in prion-diseased 
mice, both wild type and overexpressing [24]. We found 
no change in the other two signalling cascades of the UPR 
involving IRE-1-mediated XBP1 splicing (Fig. 1c) and 
cleavage of ATF6 (data not shown) throughout the time 
course of disease in rTg4510 transgene-positive mice, con-
sistent with findings in prion-infected mice [23].
Consistent with PERK branch eIF2α-P activation, 
rates of global protein synthesis measured in brain slices 
of tau+P301L mice had declined to ~40 % of those seen in 
non-transgenic littermates by 6 months of age, remaining 
repressed until 11 months (Fig. 1d), after which time the 
animals were killed. Protein synthesis rates were normal up 
to 5 months of age, suggesting the onset of sustained trans-
lational repression is between 5 and 6 months (Fig. 1d). 
Levels of the pre- and post-synaptic proteins SNAP25 and 
PSD-95 were equivalent in transgene-positive and -negative 
mice at 4 months, but reduced in tau+P301L mice at 6 months 
(Fig. 1e), reflecting the drop in protein synthesis due to 
high levels of eIF2α-P at this time. As in prion-diseased 
mice [24], the onset of eIF2α-P-mediated translational 
repression was closely associated with onset of neurode-
generation at 6 months in rTg4510 mice, which is absent at 
4 months (Fig. 1f).
To confirm that activation of PERK-eIF2α-P signalling 
is indeed the result of mutant tau expression in rTg4510 
tau+P301L mice, we tested the effect of repressing tau levels 
on eIF2α-P and ATF4 levels using doxycycline administra-
tion. Treatment of transgene-positive mice with doxycy-
cline from 4 months resulted in marked reduction in total 
tau levels by 8 months (although not as low as levels in 
transgene-negative controls that express only murine tau) 
(Fig. 1g). This produced a corresponding marked reduc-
tion in eIF2α-P and ATF4 levels compared to levels seen 
in untreated tau+P301L mice, and equivalent to those seen in 
non-transgenic mice (Fig. 1g). Our data are, therefore, con-
sistent with UPR activation being a direct result of elevated 
levels of mutant total tau in these mice. Consistent with 
this, reduced PERK-P immunostaining after doxycycline 
treatment in rTg4510 mice has also been reported by oth-
ers [1].
Thus, the onset of PERK/eIF2α-mediated translational 
repression is closely associated with synaptic protein loss 
and onset of neurodegeneration in mutant tau-express-
ing rTg4510 mice, similar to the temporal relationship 
between these events in prion-diseased animals [24]. 
Importantly, although it is true that levels of mutant tau 
overexpression are very high in this model, the pR5 mouse 
model of tauopathy in which levels of mutant tau expres-
sion are much lower, at ~70 % endogenous tau, also shows 
UPR activation [17, 18]. This is similar to the detection of 
PERK/eIF2α activation in prion-diseased mice, which is 
seen in both PrP overexpressing and wild-type mice [24], 
and is, therefore, unlikely to reflect an artefact of protein 
overexpression.
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Fig. 1  Mutant tau-expressing rTg4510 mice show overactivation of 
the PERK/eIF2α-P branch of the UPR resulting in a decline in pro-
tein synthesis rates by 6 months of age. a Scheme depicting disease 
progression in rTg4510 tau+P301L mice from 3 to 8 months (mo). Red 
circles indicate times of testing. b tau+P301L mice (black bars) show 
sustained elevated levels of eIF2α-P and ATF4 by 6 months of age, 
compared to levels seen in tau−P301L (white bars). These remained ele-
vated at 8 months, eIF2α-P and ATF4 were equivalent in both mutant 
tau-expressing and transgene-negative mice examined at 4 months. 
Levels of GADD34 do not change throughout disease progression and 
remain equivalent to tau−P301L mice. Representative immunoblots of hip-
pocampal lysates and bar charts quantitating relative levels of protein 
(n = 3) are shown. c RT-PCR of XBP1 transcript shows that there is 
no splicing in mutant tau-expressing and transgene-negative mice. 
Control lanes from untreated MEF cells (−Tm), or MEF cells treated 
with tunicamycin (+Tm) as a positive control for activation of IRE1 d 
Protein synthesis rates in hippocampal slices, determined by incorpo-
ration of 35S-methionine into protein, declined by ~57 % by 6 months 
of age in tau+P301L mice in contrast to transgene-negative mice, consist-
ent with eIF2α-P signalling (n = 3–4 mice per time point). e Levels 
of pre-synaptic protein (SNAP25) and post-synaptic protein (PSD-95) 
declined in parallel (n = 3, measured relative to GAPDH). f tau+P301L 
mice showed neuronal loss in the CA1 region of the hippocampus by 
6 months (panel iv) compared to age-matched tau−P301L mice (panel ii). 
Representative images or hematoxylin and eosin-stained sections, scale 
bar 50 μm. g Doxycycline treatment from 4 months of age reduced 
total tau protein levels (green bars) compared to non-treated tau+P301L 
mice (black bars) at 8 months of age, with accompanying reduction in 
eIF2α-P and ATF4 levels in 8-month-old tau+P301L mice to levels sim-
ilar to those seen in transgene-negative mice; and in contrast to high 
levels seen in untreated tau+P301L. Bar charts quantitating levels of total 
tau, eIF2α-P and ATF4 measured relative to GAPDH (in 3–4 independ-
ent samples) are shown. All bar charts show mean ± SEM, *p < 0.05, 
**p < 0.005, Student’s t test was used except in (c), where one-way 
ANOVA analysis with Tukey’s post hoc test for multiple comparisons 
was performed. X-axis represents increasing age in months. 
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PERK inhibitor treatment reduces eIF2α‑P levels 
and restores global translation rates
Given the known neuroprotective effects of restoring pro-
tein synthesis rates in prion-diseased mice downstream 
of misfolded PrP accumulation [11, 23], we first asked 
if restoring translation through PERK inhibition in tau 
transgene-expressing mice was similarly neuroprotective. 
We treated tau+P301L mice with the specific PERK inhibitor 
GSK2606414 [4] or vehicle alone from ~6 months of age, 
when eIF2α-P levels are known to be elevated (Fig. 1b) 
and neuronal loss is beginning (Fig. 1f; [31]). (These were 
proof-of-principle studies, as GSK2606414 is known to 
produce pancreatic toxicity despite profound neuroprotec-
tion after prolonged treatment in prion-diseased mice [23]. 
The question was whether similar neuroprotective effects 
of reversing translational repression—achieved through 
PERK inhibition—are seen in this model; not whether 
GSK2606414 is a viable treatment).
rTg4510 tau+P301L mice received 50 mg/kg GSK2606414 
(n = 10) or vehicle (n = 8) by oral gavage twice daily, 
a dose optimised for good levels of brain penetration, 
as described in [23], for 2 months (Fig. 2a). At this time 
point, at 8 months of age, animals were killed for analysis. 
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Fig. 2  PERK inhibitor treatment reduces eIF2α-P and ATF4 protein 
levels and restores protein synthesis rates in mutant tau-expressing 
rTg4510 mice. a tau+P301L mice were treated twice daily by oral gav-
age from 6 months with either the PERK inhibitor, GSK2606414 
50 mg/kg, (blue bars) or vehicle (grey bars) and tested at 8 months 
of age. b Immunostaining showed a significant reduction in PERK-P 
(red) and pSer202/Thr205-tau (AT8, green) staining in the hippocampus 
after GSK2606414 treatment. Graphs show quantification of relative 
intensity for PERK-P and ptau compared to transgene-negative mice 
(n = 3–5 mice, scale bar 20 μm). c PERK inhibitor treatment mark-
edly reduced PERK-P, eIF2α-P and ATF4 protein levels in 8-month-
old tau+P301L mice, preventing the decline of global protein synthesis 
rates as determined by 35S-methionine incorporation into protein (d) 
in comparison to vehicle-treated animals (n = 3 mice). Representa-
tive immunoblots of hippocampal lysates and bar charts quantitating 
protein levels (in three independent samples). All bar charts show 
mean ± SEM, *p < 0.05, **p < 0.01, using Student’s t test.
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As predicted, and consistent with previous observations 
in prion-diseased mice [23], GSK2606414 treatment sig-
nificantly reduced levels of PERK-P, eIF2α-P and ATF4 
levels in tau+P301L mice, compared to vehicle-treated ani-
mals, which showed persistently elevated of levels of 
these proteins (Fig. 2b, c). Critically, PERK inhibitor treat-
ment restored global protein synthesis rates to normal in 
8-month-old tau+P301L mice, in contrast to vehicle-treated 
animals, which showed markedly reduced translation rates 
at this time point (Fig. 2d). (GSK2606414 does not affect 
eIF2α-P levels and global protein synthesis where the UPR 
is not activated [23]).
PERK inhibitor treatment is neuroprotective in FTD 
mice: reducing tau phosphorylation, and brain atrophy 
and abrogating clinical signs
Importantly, PERK inhibitor treatment was neuroprotec-
tive in rTg4510 mice, as in prion-diseased mice [23], par-
tially restoring neuronal numbers, maintaining total brain 
weight and preventing clinical signs in 8-month-old ani-
mals, and preventing any progression of neuronal loss from 
6 months of age, when treatment was begun (Fig. 3a–c). 
Thus, all vehicle-treated tau+P301L mice (8/8) showed poor 
grooming, hunched posture, hind-leg clasping and/or poor 
mobility by 8 months of age (Fig. 3a, panel ii). In contrast, 
all PERK inhibitor-treated tau+P301L mice (10/10) showed 
normal grooming, posture and movement at this stage 
(Fig. 3a, panel iii). Indeed, PERK inhibitor-treated tau+P301L 
mice were indistinguishable clinically from their transgene-
negative tau−P301L littermates (Fig. 3a, panel i). Histological 
examination confirmed marked neuroprotection in tau+P301L 
mice treated with GSK2606414, compared to vehicle-
treated mice, which showed profound hippocampal neu-
ronal loss (Fig. 3a, compare panels v and vi), characteris-
tic of the extensive forebrain neurodegeneration described 
in these mice at this stage [31]. GSK2606414 treatment 
resulted in preservation of ~60 % of CA1 neurons at 
8 months, compared to ~25 % in vehicle-treated mice at 
this time (Fig. 3b). The protective effect is notable espe-
cially given that treatment begun at 6 months, when neu-
ronal loss is already beginning in the hippocampus (Fig. 1f; 
[29, 31]). On a macroscopic scale, PERK inhibitor treat-
ment significantly reduced brain atrophy, with greater total 
brain weights compared to untreated transgene-expressing 
animals at this stage (Fig. 3c). Both the number of CA1 
neurons and brain weights of PERK inhibitor-treated ani-
mals at 8 months were very similar to neuronal numbers 
reported in untreated tau+P301L rTg4510 mice at 5.5 months 
by other workers [29, 31], supporting the fact that the com-
pound prevented further progression of neurodegeneration. 
(All tau+P301L mice treated with GSK2606414 developed 
signs of pancreatic toxicity after 2 months of treatment, as 
expected [11, 24], with weight loss and mild elevation of 
blood glucose levels).
We also examined the effect of PERK inhibition on 
pathological phosphorylated tau expression histologi-
cally and biochemically, which is central to pathology in 
all tauopathies [5]. We found that GSK2606414 treatment 
had no effect on soluble total tau levels at 8 months, which 
were indistinguishable from those of vehicle-treated mice 
(Fig. 3d). (This is not unexpected, despite the effect of 
PERK inhibition on global protein synthesis, because the 
P301L tau transgene is expressed under control of the PrP 
promoter [31], which has upstream open reading frames 
in the 5ʹ UTR that allow the protein to escape translational 
repression [24]).
However, levels of phospho-tau in rTg4510 transgenic 
mice brain were reduced by PERK inhibitor treatment. Tau 
can be phosphorylated at more then 30 different sites and 
hyperphosphorylation is crucial for aggregation and tan-
gle formation. A number of different antibodies have been 
described that recognise different tau phosphorylation sites 
and pathology, including AT8 [10, 22], which detects phos-
phorylation at Ser202/Thr205 and is a marker for pretangles 
and tangles, and PHF1 [28], which detects late-stage tan-
gles including tau phosphorylated at Ser396/404. Immunohis-
tochemistry using AT8 showed a notable decrease in total 
phospho-Ser202/Thr205 tau staining in the CA1 region of the 
hippocampus in tau+P301L mice after GSK2606414 treatment, 
with many neurons negative for AT8 staining and hence 
phosphorylated tau. In contrast, vehicle-treated tau+P301L 
mice, showed prominent AT8-positive staining in the cell 
somata of almost all remaining CA1 neurons (Figs. 2b, 3a, 
compare panels viii and ix), consistent with the findings of 
Spires and co-workers showing prominent staining of PHF1 
positive neurons in CA1 region of tau+P301LrTg4510 mice at 
8.5 months of age [36]. Transgene-negative mice did not 
show any staining for phospho-Ser202/Thr205 tau (Figs. 2b, 
3a, panel vii). Biochemical assays to quantitate reduction in 
total phospho-tau species in total lysates confirmed reduc-
tion in both pSer202/Thr205 (AT8) and pSer369/404 (PHF1) 
isoforms after PERK inhibitor treatment (Fig. 3e).
As discussed, the pathogenic role of UPR activation in 
tauopathies likely acts through two separate mechanisms. 
Thus, not only is PERK-mediated translational failure acti-
vated by high levels of misfolded/mutant tau, but UPR acti-
vation is known to also drive tau phosphorylation in vitro 
[14, 39] and in vivo [20], which can be prevented in vitro 
by PERK inhibition with GSK2606414 [39]. UPR-medi-
ated tau phosphorylation is thought to occur, at least in part, 
indirectly, through the induction of the active form, pTyr216-
isoform, of the serine/threonine kinase GSK3β that phos-
phorylates tau at disease-relevant epitopes [25]. In vivo, 
UPR activation activates GSK3β leading to tau phospho-
rylation in rat brains [20]; specific GSK3β inhibitors reduce 
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tau phosphorylation and aggregation in mouse models of 
tauopathy [27, 34]. Further, in AD brains, the active form 
of GSK3β co-localises with phospho-tau [19] and with 
PERK-P [16], which is also seen in pR5 tau-expressing 
mice [17, 18]. We, therefore, assessed levels of active and 
inactive (pSer9-) forms of GSK3β, as well as total levels of 
the enzyme in tau+P301L rTg4510 mice after PERK inhibitor 















































































































































































































































tauP301L+  + Vehicle
tauP301L+ + GSK2606414
Fig. 3  PERK inhibitor treatment decreases tau phosphorylation 
and prevents neurodegeneration and clinical disease in mutant tau-
expressing rTg4510 mice. a GSK2606414 treatment prevented clini-
cal signs in 8-month-old tau+P301L mice, which showed normal groom-
ing, posture and movement compared to vehicle-treated animals and 
were indistinguishable from transgene-negative animals of the same 
age (representative images, i–iii). Histologically, PERK inhibitor 
resulted in marked neuroprotection with preservation of hippocampal 
volume and CA1-3 neuronal ribbon (iv–vi, hematoxylin and eosin-
stained sections), and immunostaining using AT8 showed a signifi-
cant reduction in pSer202/Thr205-tau staining in the hippocampus after 
GSK2606414 treatment (vii–ix, representative images of hippocampal 
sections, scale bar 50 μm). b Average count of the number of CA1 
pyramidal neurons in five consecutive slices from tau+P301L treated 
with vehicle (grey bars) or GSK2606414 (blue bars) mice relative to 
control mice (tau−P301L, white bars) shows reduced loss of pyramidal 
neurons in PERK inhibitor-treated mice (i.e. prevention of neurode-
generation) to numbers similar to 6-month-old mutant tau-expressing 
mice (black bar) (n = 3–4 mice) (c) GSK2606414 partially prevented 
brain atrophy in comparison to vehicle-treated mice (n = 3–8 mice). 
d Total tau levels were not significantly different in PERK inhibitor 
or vehicle-treated animals (n = 3 mice). e AlphaScreen analysis with 
AT8 and PHF-1 shows a reduction in soluble phospho-tau at pSer202/
Thr205 and pSer396/404 epitopes after PERK inhibitor treatment com-
pared to vehicle-treated animals (n = 4 mice). f Levels of the active 
form, pTyr216-GSK3β, and total GSK3β levels increased compared to 
control mice. PERK inhibitor treatment significantly reduced pTyr216-
GSK3β and total GSK3β levels in tau+P301L mice to levels seen in con-
trol mice. Representative immunoblots of hippocampal lysates and bar 
charts quantitating protein levels (in three independent samples). All 
bar charts show mean ± SEM, *p < 0.05, **p < 0.01 ***p < 0.005, n.s 
non-significant, using Student’s t test.
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of active pTyr216-GSK3β, and total levels were increased in 
vehicle-treated tau+P301L mice at 8 months, but these were 
reduced to levels seen in transgene-negative mice by PERK 
inhibitor treatment (Fig. 3f). The data are consistent with 
PERK inhibitor-mediated suppression of GSK3β activ-
ity resulting in reduced phosphorylation of tau and mark-
edly lower levels pathological tau staining in the brains of 
treated animals compared to vehicle-treated controls. We 
noted that total levels of GSK3β increased in mutant tau-
expressing mice (Fig. 3f). The reasons for this are unclear. 
GSK3β mRNA does not contain upstream open reading 
frames (uORFs) in its 5ʹ untranslated region (as does ATF4, 
for example), nor does it have relevant transcriptional regu-
latory sequences (data not shown).
Therefore, activation of the UPR may also result in per-
sistent activation of GSK3β and contribute further to the 
neurodegenerative process by resulting in a vicious cycle 
of sustained UPR activation/tau phosphorylation. Treat-
ments modifying PERK/eIF2α signalling may, therefore, 
be beneficial not only by restoring vital protein synthesis 
rates in compromised neurons, but also by decreasing the 
phosphorylation of tau, doubly reducing the toxic burden 
in these diseases. The data are of interest also because of 
opposing mechanisms in mouse models of specific famil-
ial ALS mutations and the rare peripheral neuropathy 
CMT1B, where genetic and pharmacological interventions 
that maintain high levels of eIF2α-P, rather than reducing it 
(at least in early disease) are protective [7, 8, 32, 40]. Thus, 
defining the effects of PERK pathway activation and its 
inhibition in a wide range of neurodegenerative disorders is 
crucial for effective intervention.
In conclusion, we have shown that UPR-mediated trans-
lational repression is associated with neurodegeneration in 
a mouse model of Frontotemporal Dementia, and that UPR 
activation also drives pathogenic tau phosphorylation in these 
mice. We have shown that neurodegeneration is significantly 
reduced that levels of phospho-tau decline and clinical dis-
ease is prevented by oral treatment with the PERK inhibitor, 
GSK2606414. The data support the conclusion that UPR dys-
regulation, at least in part, mediates tau neurodegeneration, 
as well as prion neurodegeneration [23, 24]. Given the preva-
lence of UPR activation in AD and related dementias, our data 
provide an increasingly compelling argument for the develop-
ment neuroprotective therapies aimed at restoring neuronal 
protein synthesis rates, at least in part [11], and reducing phos-
phorylation of tau, for treatment of these diseases.
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